Treatment-Resistant Depression in Portugal

Detalhes bibliográficos
Autor(a) principal: Bessa, João M.
Data de Publicação: 2022
Outros Autores: Carvalho, Serafim, Cunha, Inês B., Fernandes, Milene, Matos-Pires, Ana, Neves, Rui, Oliveira-Maia, Albino J., Santos, Susana, Santos, Vítor
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/137122
Resumo: Funding Information: SS is an employee of Janssen-Cilag Farmacêutica Lda. MF is an employee of CTI Clinical Trial and Consulting Services. The remaining authors received advisory board fees from Janssen-Cilag Farmacêutica Lda. AO-M was the national coordinator for Portugal of a non-interventional study EDMS-ERI-143085581, 4.0 to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. 2019–2020; is the recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests; and is the national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. EudraCT numbers 2017-003288-36 and 2020-001348-25, and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. EudraCT Number: 2019-002992-33. Janssen had no influence on the interpretation of results. This manuscript presents the opinion of the psychiatry experts only. Funding Information: Support for third-party advisory board logistics and writing assistance, provided by CTI Clinical Trial and Consulting Services, was funded by Janssen-Cilag Farmacêutica Lda in accordance with Good Publication Practice (GPP3) guidelines. Publisher Copyright: Copyright © 2022 Bessa, Carvalho, Cunha, Fernandes, Matos-Pires, Neves, Oliveira-Maia, Santos and Santos.
id RCAP_cb36e44313d5c9f9dc6204a23d7d6f23
oai_identifier_str oai:run.unl.pt:10362/137122
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Treatment-Resistant Depression in PortugalPerspective From Psychiatry Expertsexpert opinionmajor depressive disorderpatient journeyPortugaltreatment-resistant depressionPsychiatry and Mental healthSDG 3 - Good Health and Well-beingFunding Information: SS is an employee of Janssen-Cilag Farmacêutica Lda. MF is an employee of CTI Clinical Trial and Consulting Services. The remaining authors received advisory board fees from Janssen-Cilag Farmacêutica Lda. AO-M was the national coordinator for Portugal of a non-interventional study EDMS-ERI-143085581, 4.0 to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. 2019–2020; is the recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests; and is the national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. EudraCT numbers 2017-003288-36 and 2020-001348-25, and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. EudraCT Number: 2019-002992-33. Janssen had no influence on the interpretation of results. This manuscript presents the opinion of the psychiatry experts only. Funding Information: Support for third-party advisory board logistics and writing assistance, provided by CTI Clinical Trial and Consulting Services, was funded by Janssen-Cilag Farmacêutica Lda in accordance with Good Publication Practice (GPP3) guidelines. Publisher Copyright: Copyright © 2022 Bessa, Carvalho, Cunha, Fernandes, Matos-Pires, Neves, Oliveira-Maia, Santos and Santos.Guidance about treatment-resistant depression (TRD) in Portugal is very limited, even though depression prevalence is among the highest in European countries. A questionnaire was conducted, followed by two advisory boards with seven Portuguese psychiatry experts, to characterize and discuss MDD and TRD epidemiology, diagnosis, patient journey, treatment options, and unmet clinical needs. Consensus was reached on the main issues. In daily practice, TRD can be defined as moderate to severe MDD episodes with insufficient clinical improvement after two antidepressant treatments, taken in adequate doses and duration. TRD diagnosis and treatment are mostly decided by psychiatrists at public hospitals. Treatment type and duration must be adjusted to characteristics of the patient and the depressive episode, including symptoms, number of previous episodes, comorbidities, and previous treatment response and side effects. The most relevant objectives of TRD treatment are reaching response and remission, prevention of suicide, and improvement of quality of life, functionality, and wellbeing. Regarding pharmacotherapy, antidepressant switch occurs more frequently with non-response, while optimization, combination, and augmentation are considered for patients with partial response. Psychotherapy should be considered in parallel to pharmacological treatment. Brain stimulation techniques are underused. Lifelong treatment is required for recurrent or more chronic TRD episodes, but patient adherence is also poorer in these cases. In Portugal, TRD management is limited by lack of access to specialist care and to many treatment options. These aspects highlight that conventional pharmacotherapy does not lead to remission in many patients and that optimization strategies are frequently necessary to achieve satisfactory treatment outcomes.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Comprehensive Health Research Centre (CHRC) - pólo NMSRUNBessa, João M.Carvalho, SerafimCunha, Inês B.Fernandes, MileneMatos-Pires, AnaNeves, RuiOliveira-Maia, Albino J.Santos, SusanaSantos, Vítor2022-04-28T22:34:14Z2022-03-302022-03-30T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/137122eng1664-0640PURE: 43540042https://doi.org/10.3389/fpsyt.2022.824919info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:14:49Zoai:run.unl.pt:10362/137122Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:48:48.227954Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Treatment-Resistant Depression in Portugal
Perspective From Psychiatry Experts
title Treatment-Resistant Depression in Portugal
spellingShingle Treatment-Resistant Depression in Portugal
Bessa, João M.
expert opinion
major depressive disorder
patient journey
Portugal
treatment-resistant depression
Psychiatry and Mental health
SDG 3 - Good Health and Well-being
title_short Treatment-Resistant Depression in Portugal
title_full Treatment-Resistant Depression in Portugal
title_fullStr Treatment-Resistant Depression in Portugal
title_full_unstemmed Treatment-Resistant Depression in Portugal
title_sort Treatment-Resistant Depression in Portugal
author Bessa, João M.
author_facet Bessa, João M.
Carvalho, Serafim
Cunha, Inês B.
Fernandes, Milene
Matos-Pires, Ana
Neves, Rui
Oliveira-Maia, Albino J.
Santos, Susana
Santos, Vítor
author_role author
author2 Carvalho, Serafim
Cunha, Inês B.
Fernandes, Milene
Matos-Pires, Ana
Neves, Rui
Oliveira-Maia, Albino J.
Santos, Susana
Santos, Vítor
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Comprehensive Health Research Centre (CHRC) - pólo NMS
RUN
dc.contributor.author.fl_str_mv Bessa, João M.
Carvalho, Serafim
Cunha, Inês B.
Fernandes, Milene
Matos-Pires, Ana
Neves, Rui
Oliveira-Maia, Albino J.
Santos, Susana
Santos, Vítor
dc.subject.por.fl_str_mv expert opinion
major depressive disorder
patient journey
Portugal
treatment-resistant depression
Psychiatry and Mental health
SDG 3 - Good Health and Well-being
topic expert opinion
major depressive disorder
patient journey
Portugal
treatment-resistant depression
Psychiatry and Mental health
SDG 3 - Good Health and Well-being
description Funding Information: SS is an employee of Janssen-Cilag Farmacêutica Lda. MF is an employee of CTI Clinical Trial and Consulting Services. The remaining authors received advisory board fees from Janssen-Cilag Farmacêutica Lda. AO-M was the national coordinator for Portugal of a non-interventional study EDMS-ERI-143085581, 4.0 to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. 2019–2020; is the recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests; and is the national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. EudraCT numbers 2017-003288-36 and 2020-001348-25, and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. EudraCT Number: 2019-002992-33. Janssen had no influence on the interpretation of results. This manuscript presents the opinion of the psychiatry experts only. Funding Information: Support for third-party advisory board logistics and writing assistance, provided by CTI Clinical Trial and Consulting Services, was funded by Janssen-Cilag Farmacêutica Lda in accordance with Good Publication Practice (GPP3) guidelines. Publisher Copyright: Copyright © 2022 Bessa, Carvalho, Cunha, Fernandes, Matos-Pires, Neves, Oliveira-Maia, Santos and Santos.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-28T22:34:14Z
2022-03-30
2022-03-30T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/137122
url http://hdl.handle.net/10362/137122
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1664-0640
PURE: 43540042
https://doi.org/10.3389/fpsyt.2022.824919
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138088426930176

Registros relacionados